Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial

A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic... Companion diagnostic tests play an important role in precision medicine. With the advancement of new technologies, multiple companion diagnostic tests can be rapidly developed in multiple platforms and use different samples to select patients for new treatments. Analytically validated assays must be clinically evaluated before they can be implemented in patient management. The status quo design for validating candidate assays is to employ one candidate assay to select patients for new drug clinical trial and then further evaluate the 2nd candidate assay in a bridging study. We propose a new enrollment strategy that employs two assays to select patients. We then develop a bivariate Bayesian approach that enables the totality of data to be used in evaluating whether these assays can be used independently or in a composite procedure in selecting right patients for new treatment. We demonstrate through simulations that when proper priors are available, the Bayesian approach is superior to classical methods in terms of statistical power. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biostatistics & Epidemiology Taylor & Francis

A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial

Biostatistics & Epidemiology , Volume 5 (2): 11 – Jul 3, 2021

A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial

Abstract

Companion diagnostic tests play an important role in precision medicine. With the advancement of new technologies, multiple companion diagnostic tests can be rapidly developed in multiple platforms and use different samples to select patients for new treatments. Analytically validated assays must be clinically evaluated before they can be implemented in patient management. The status quo design for validating candidate assays is to employ one candidate assay to select patients for new drug...
Loading next page...
 
/lp/taylor-francis/a-bivariate-bayesian-framework-for-simultaneous-evaluation-of-two-4KzIh1JfIl
Publisher
Taylor & Francis
Copyright
© 2021 International Biometric Society – Chinese Region
ISSN
2470-9379
eISSN
2470-9360
DOI
10.1080/24709360.2021.1913705
Publisher site
See Article on Publisher Site

Abstract

Companion diagnostic tests play an important role in precision medicine. With the advancement of new technologies, multiple companion diagnostic tests can be rapidly developed in multiple platforms and use different samples to select patients for new treatments. Analytically validated assays must be clinically evaluated before they can be implemented in patient management. The status quo design for validating candidate assays is to employ one candidate assay to select patients for new drug clinical trial and then further evaluate the 2nd candidate assay in a bridging study. We propose a new enrollment strategy that employs two assays to select patients. We then develop a bivariate Bayesian approach that enables the totality of data to be used in evaluating whether these assays can be used independently or in a composite procedure in selecting right patients for new treatment. We demonstrate through simulations that when proper priors are available, the Bayesian approach is superior to classical methods in terms of statistical power.

Journal

Biostatistics & EpidemiologyTaylor & Francis

Published: Jul 3, 2021

Keywords: biomarker; circulating DNA; Bayesian analysis; clinical trial eligibility; companion diagnostic

References